Frontlight ResearchEarly access
Taking peopleNo phase
Multimodal Biomarkers Predicting Medication-Induced Adverse Effects in Children With ADHD
Key facts
- Who runs it
- National Taiwan University Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 90 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 31 Jul 2029
- Type of study
- Observational
- Treatments tested
- methylphenidate
- Record updated
- 28 October 2026
Who can take part
- Age
- 6 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Participants, between the ages of 6 and 16 must meet the DSM-5 criteria for ADHD
- At the time of initial evaluation, participants must exhibit a score greater than 3 on the Clinical Global Impressions scale for ADHD Severity (CGI-ADHD-S)
- Cognitive assessment of participants must demonstrate a Full-Scale Intelligence Quotient (FSIQ) greater than 80
Who cannot take part
- Individuals with any prior exposure to pharmacological treatments specifically intended for managing ADHD symptoms will be excluded
- Individuals with comorbid major psychiatric disorders-including autism spectrum disorder (ASD), psychotic disorders, mood disorders, or substance use disorders-will be excluded
- Individuals with major neurological conditions, such as epilepsy or other central nervous system disorders, will be excluded
- Individuals with serious systemic medical conditions, including diabetes mellitus or cardiovascular disease, will be excluded
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 6 and 16 years old?
This trial is currently available in Taiwan.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To build a multimodal model combining neuropsychological, neurophysiological, and metabolomic measures to identify biomarkers predicting MPH-induced adverse effects and their underlying mechanisms, supporting individualized risk assessment in clinical practice.
The group in the trial
- ADHD GROUP
Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
Treatment: methylphenidate
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multimodal Neurobiological Investigation of Biomarkers Predicting Medication-Induced Adverse Effects in Children With Attention-Deficit/Hyperactivity Disorder
- Criteria questions
- Built from NCT07900451, who can take part
- Record updated
- 28 October 2026